Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation
Open Access
- 20 January 2011
- journal article
- research article
- Published by Springer Nature in BMC Urology
- Vol. 11 (1) , 1
Abstract
Background: Unimpaired HLA class I antigen presentation is a prerequisite for the recognition of tumor cells by cytotoxic T lymphocytes and thus essential for the success of anticancer immunotherapeutic concepts. Several approaches have been taken in the immunotherapy of metastatic renal cell carcinoma (RCC), however of limited success. HLA loss or down-regulation have often been reported and might interfere with immunotherapeutic approaches aimed at the recognition of HLA-presented peptides.Methods: We employed a quantitative method of molecular analysis for the comparison of HLA amounts on primary tumor, normal kidney and metastases of RCC, using Edman degradation. We analyzed a series of 47 RCC samples including corresponding renal parenchyma, local lymph node metastases and distant metastases.Results: Results of quantitative Edman degradation revealed significantly higher HLA yields on primary tumor and metastases compared to normal kidney tissue. This effect was shown not to result from infiltrating immune cells, since tumor-infiltrating lymphocytes had no influence on the overall HLA recovery from tumor tissue. Unexpectedly, we found a higher amount of HLA class I molecules on distant metastases compared to local lymph node metastases.Conclusion: Edman degradation allows the direct quantitative comparison of HLA class I protein expression by tumor or normal tissue and metastases of RCC patients. Our results raise hopes for improving the success and effectiveness of future immunotherapeutic concepts for metastatic RCC.Keywords
This publication has 35 references indexed in Scilit:
- Higher HLA class I expression in renal cell carcinoma than in autologous normal tissueTissue Antigens, 2010
- A Cryptic Vascular Endothelial Growth Factor T-Cell Epitope: Identification and Characterization by Mass Spectrometry and T-Cell AssaysCancer Research, 2008
- Phase I trial of personalized peptide vaccination for cytokine‐refractory metastatic renal cell carcinoma patientsCancer Science, 2007
- Human Leukocyte Antigen Class I Antigen Expression Is an Independent Prognostic Factor in Ovarian CancerClinical Cancer Research, 2007
- Down-Regulation of HLA Class I Antigen is an Independent Prognostic Factor for Clear Cell Renal Cell CarcinomaJournal of Urology, 2007
- Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinomaTissue Antigens, 2006
- Vaccines in Renal Cell CarcinomaSeminars in Oncology, 2006
- Effect of Human Leukocyte Antigen Class I Expression of Tumor Cells on Outcome of Intravesical Instillation of Bacillus Calmette-Guerin Immunotherapy for Bladder CancerClinical Cancer Research, 2006
- Down-Regulation of HLA Class I Antigen Processing Molecules: An Immune Escape Mechanism of Renal Cell Carcinoma?Journal of Urology, 2004
- Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC moleculesNature, 1991